Navigation Links
Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
Date:9/6/2007

boratory abnormalities of clinical

significance were noted.

-- Part 2 is a multiple ascending dose study of R7128 conducted in 40

patients chronically infected with HCV genotype 1 who have previously

failed interferon therapy. The primary objective of Part 2 is to

assess the safety, tolerability and pharmacokinetics of R7128 after

once-daily or twice-daily dosing for 14 days. The secondary objective

is to assess antiviral efficacy by measuring the change in HCV RNA.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The WHO estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost four million people in the United States have been infected with HCV, of whom 2.7 million are chronically infected.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: (609) 613-4125

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that there will be a delay in the presentation of R7128 data at upcoming conferences, the risk that the R7128 data to be presented at upcoming conferences is not accurate or representative, the risk that the preliminary data from the R7128 Phase 1 Study is not accurate or representative, the risk that our collaboration with Roche will not continue or will not be successful, the risk that the on-going or anticipated clinical trials for any one or more o
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Advantages of Roche Applied Science amplification products
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. NimbleGen to discontinue IPO after Roches $272.5 million acquisition
5. Prodesse enters patent agreement with Roche
6. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
7. Wisconsin firms to present at Cleantech venture capital event
8. New Sonic Foundry search engine finds words, phrases in video presentations
9. Lone Wisconsin firm to present at InvestMidwest
10. Sonic Foundry creates search engine for 7,000 expert video presentations
11. InvestMidWest calls for business presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Bed bugs have become so widespread in the ... turn to chemical-based pesticides for help to completely get rid ... those solutions present, the company advised the public to ... , According to My Cleaning Products, chemical-based pesticides are not ... It shared that the pests have already developed immunity to ...
(Date:5/21/2013)... MN (PRWEB) May 21, 2013 Revolutionary ... patented automatic colony counter, announced today that they have ... products , the IncuCount, IntelliCount, InCount and ImpressCount. ... and sophistication are especially useful in food microbiology and ... given an updated look. A bright white enclosure ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 NANONEX ... nanoimprint solutions , today announced the successful delivery ... manufacturing system, the NX-M200B, to a major Japanese ... is a fully-automated, production-ready, advanced nanoimprint lithography tool ... of wafer and substrate sizes and types. Based ...
(Date:5/21/2013)... Ontario (PRWEB) May 21, 2013 ... scientists of the ITN to design the study, ... of two key clinical models used in the ... (EEC) and Nasal Allergen Challenge (NAC) models. Although ... by numerous publications, to date no direct comparison ...
Breaking Biology Technology:New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing 2Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2
... /PRNewswire-FirstCall/ Varian, Inc. (NasdaqGS:,VARI) announced that its Board ... new director. Glover is the seventh member of ... a term expiring at the annual meeting of,the ... Vice President, Operations and Chief Financial Officer,of Anadys ...
... May 7 Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ) ... 31, 2008., Total revenues in the first quarter ... the first quarter of 2007, and included $2.0 million ... $0.6 million in patent reimbursements from Arena,s collaborations with,Merck ...
... to Provide Full Functional Validation Data for Its MISSION(R) ... ... LOUIS, May 7 Sigma-Aldrich(TM) (Nasdaq:,SIAL) and the second phase ... Consortium,s collection of approximately,160,000 previously-cloned lentiviral-based shRNA vector constructs.,Currently, more ...
Cached Biology Technology:James T. Glover Appointed to Board of Directors of Varian, Inc. 2Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 2Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 3Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 4Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 5Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 6Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 7Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 8Sigma-Aldrich Joins Phase 2 of The RNAi Consortium to Validate shRNA Libraries 2Sigma-Aldrich Joins Phase 2 of The RNAi Consortium to Validate shRNA Libraries 3
(Date:5/21/2013)... , May 21, 2013 Royal Philips ... xMATRIX, the world,s first portable ultrasound with Philips, industry ... (ICE) capability. The CX50 xMATRIX with available Live 3D ... Paris at the EuroPCR, official meeting for ... 21-24. Since its launch in 2012, Philips ...
(Date:5/21/2013)... The epigenetic modifications, which alter the way genes ... apparently be detected in the blood of pregnant ... way to foretell depression in the weeks after ... symptoms become debilitating. , The findings of the ... online in the journal Molecular Psychiatry . ...
(Date:5/20/2013)... antibiotic colistin are also commonly resistant to antimicrobial ... a study in mBio , the online ... Cross-resistance to colistin and host antimicrobials LL-37 and ... attack, could mean that patients with life-threatening multi-drug ... immune response. Colistin is a last-line drug for ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... Spring Harbor, NY A team of neuroscientists at Cold ... to a GPS system for locating and tracking a vital ... identification, particularly in living animals. The cells ... neurotransmitter called GABA (gamma aminobutyric acid). GABA neurons function ...
... mussels, squids as different as they may look, ... to the phylum Mollusca , also called molluscs. ... and Professor Ken Halanych, USA, with the participation of ... research into the relationships among different molluscs as part ...
... to make pest insects buzz off for good or even ... a tiny finding with enormous potential. Sujata Chaudhari, a ... the senior author of a study that was published this ... Sciences , also called PNAS. Her work includes a discovery ...
Cached Biology News:Team creates genetic 'GPS' system to comprehensively locate and track inhibitory nerve cells 2Team creates genetic 'GPS' system to comprehensively locate and track inhibitory nerve cells 3Team creates genetic 'GPS' system to comprehensively locate and track inhibitory nerve cells 4Research into molluscan phylogeny reveals deep animal relationship of snails and mussels 2Research into molluscan phylogeny reveals deep animal relationship of snails and mussels 3From protein to planes and pigskin 2From protein to planes and pigskin 3
... linear ion trap mass spectrometer enables high-throughput ... The LXQ linear ion trap mass spectrometer ... applications, delivering the fast cycle time and ... trap at an attractive price. The ...
... developed specifically for reduced mutagenicity to be ... agarose or acrylamide gels. SYBR Safe stain is ... SYBR Safe stain's detection sensitivity is better than ... as a premixed solution that can be used ...
... These are just some the things youll ... of Protein-Protein Interactions, edited by Erica Golemis, One ... skillfully edited compilation of topics in protein interaction ... text that must be a part of your ...
... This exceptionally sensitive nucleic acid gel stain ... low background in gels, making it ideal for ... standard UV transilluminators. SYBR Green I nucleic ... in capillary electrophoresis, real-time PCR assays and bandshift ...
Biology Products: